Ozempic Gastroparesis Attorney: Understanding the Statute of Limitations for Ozempic in Florida

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Guidance to Targeted Legal Inquiry

For decades, public health communication has centered on broad, accessible guidance—encouraging informed choices about nutrition, physical activity, and routine medical screenings. This general health and science information framework served as a foundation for helping individuals navigate wellness in an era of rising chronic disease awareness. As medical knowledge advanced, so did the complexity of therapeutic options, including the introduction of glucagon-like peptide-1 receptor agonists for metabolic conditions. These medications, while effective for their intended purposes, have prompted new questions about long-term safety profiles that extend beyond initial prescribing contexts. In the current landscape, a specific concern has emerged regarding the association between certain GLP-1 medications and delayed gastric emptying, a condition that can significantly impair quality of life. For individuals who have used such therapies and subsequently developed gastrointestinal complications, the focus shifts from general health maintenance to a more targeted inquiry: understanding legal recourse when adverse effects are linked to pharmaceutical exposure. In Florida, this transition requires careful attention to statutory deadlines that govern product liability claims. The statute of limitations for filing an action related to Ozempic exposure and gastroparesis risk is a critical factor, as it determines the window within which affected individuals may seek accountability. This pivot from broad health education to specific therapeutic exposure concerns underscores the evolving nature of patient advocacy in the context of modern pharmacotherapy.

Understanding Ozempic and Its Association with Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action involves slowing gastric emptying, which can lead to gastrointestinal adverse reactions. Among these, gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction—has been reported in association with Ozempic use. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, bloating, and abdominal pain, which overlap with common Ozempic side effects. Diagnosis typically requires gastric emptying scintigraphy or breath testing to confirm delayed emptying. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions with a frequency of <5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (placebo 6.1%, 0.5 mg 15.8%, 1 mg 20.3%), vomiting (2.3%, 5.0%, 9.2%), diarrhea (1.9%, 8.5%, 8.8%), abdominal pain (4.6%, 7.3%, 5.7%), and constipation (1.5%, 5.0%, 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanisms Linking Ozempic to Gastroparesis and Diagnostic Challenges

Mechanistic pathways linking Ozempic to gastroparesis involve GLP-1 receptor activation in the gastrointestinal tract, which inhibits gastric motility and delays gastric emptying. This effect is dose-dependent and can persist beyond the initial dose escalation period. Chronic use may lead to sustained impairment of gastric function, potentially progressing to clinically significant gastroparesis. The overlap between common Ozempic side effects and gastroparesis symptoms complicates diagnosis, as patients may attribute persistent nausea, vomiting, and abdominal pain to the medication's expected effects rather than a distinct pathological condition. Regarding adequacy of warnings, the Ozempic prescribing information lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a separate adverse event. The label notes that gastrointestinal reactions occurred more frequently with Ozempic than placebo and that discontinuation rates due to these reactions were higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of the potential for this serious condition. This gap in labeling could be relevant for patients who develop persistent gastrointestinal symptoms requiring medical evaluation and treatment.

Florida Statute of Limitations for Ozempic-Related Product Liability Claims

For affected patients in Florida, attorney-related considerations include the statute of limitations for product liability claims. In Florida, the statute of limitations for personal injury claims is generally four years from the date of injury, but for product liability actions, it is typically two years from the date the injury was discovered or should have been discovered. Given the timeline between exposure to Ozempic and documented harm, patients should be aware that the clock may start when they first experience symptoms consistent with gastroparesis, such as persistent nausea, vomiting, or abdominal pain, and when a diagnosis is confirmed. The delay between initial symptoms and formal diagnosis can affect the statute of limitations, as the injury may not be immediately recognized as related to Ozempic. Patients should consult with an attorney to determine the applicable deadlines based on their specific circumstances. In summary, Ozempic use is associated with gastrointestinal adverse reactions that can mimic or cause gastroparesis. The prescribing information does not explicitly warn about gastroparesis, which may affect patient awareness and legal claims. Florida's statute of limitations for product liability claims requires timely action, and patients should seek legal advice promptly if they suspect harm from Ozempic. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for filing an Ozempic gastroparesis lawsuit in Florida?

In Florida, the statute of limitations for product liability claims is generally two years from the date the injury was discovered or should have been discovered. For personal injury claims, it is four years. Patients should consult an attorney to determine the applicable deadline based on their specific circumstances.

Does Ozempic's prescribing information warn about gastroparesis?

No, the Ozempic prescribing information lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a separate adverse event. This lack of specific warning may affect patient awareness and legal claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.